Cargando…
The risk factors of toxicity during chemotherapy and radiotherapy in breast cancer patients according to the presence of BRCA gene mutation
AIM OF THE STUDY: Treatment toxicity may decrease the treatment effectiveness due to the need to reduce the dose or increase the interval between cycles. The aim of this study was to distinguish the risk factors for treatment side effects in breast cancer patients and to assess the impact of BRCA1/2...
Autores principales: | Huszno, Joanna, Budryk, Magdalena, Kołosza, Zofia, Nowara, Elżbieta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4507882/ https://www.ncbi.nlm.nih.gov/pubmed/26199574 http://dx.doi.org/10.5114/wo.2015.50014 |
Ejemplares similares
-
Outcome of COVID-19 infection in cancer patients during active systemic anticancer treatment. Single-institution experience. A retrospective analysis
por: Nowara, Elżbieta, et al.
Publicado: (2021) -
Clinicopathological characteristics of breast cancer patients with NOD2 mutation according to age
por: Huszno, Joanna, et al.
Publicado: (2020) -
Treatment related toxicity in BRCA1-associated epithelial ovarian cancer – is DNA repairing impairment associated with more adverse events?
por: Badora-Rybicka, Agnieszka, et al.
Publicado: (2016) -
Checkpoint Kinase 2 (CHEK2) Mutation in Renal Cell Carcinoma: A Single-Center Experience
por: Huszno, Joanna, et al.
Publicado: (2018) -
Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib
por: Nowara, Elzbieta, et al.
Publicado: (2016)